These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6401998)

  • 21. Transient concentrations and agonist potency of PGH2 in platelet activation by endogenous arachidonate.
    Hornberger W; Patscheke H
    Eicosanoids; 1989; 2(4):241-8. PubMed ID: 2517034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of imidazole as a selective inhibitor thromboxane synthetase in human platelets.
    Needleman P; Raz A; Ferrendelli JA; Minkes M
    Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1716-20. PubMed ID: 193113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of arachidonate-induced human platelet aggregation by a single low oral dose of aspirin in combination with a thromboxane synthase inhibitor.
    Cerletti C; Rajtar G; Bertelé V; de Gaetano G
    Thromb Haemost; 1984 Oct; 52(2):215. PubMed ID: 6441306
    [No Abstract]   [Full Text] [Related]  

  • 24. The effects of dazoxiben, an inhibitor of thromboxane synthetase, on cold-induced forearm vasoconstriction and platelet behaviour in different individuals.
    Cowley AJ; Jones EW; Carter AJ; Hanley SP; Heptinstall S
    Br J Clin Pharmacol; 1985 Jan; 19(1):1-8. PubMed ID: 2983748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors.
    Gorman RR
    Adv Prostaglandin Thromboxane Res; 1980; 6():417-25. PubMed ID: 6247892
    [No Abstract]   [Full Text] [Related]  

  • 26. Suppression of foam cell lesions in hypercholesterolemic rabbits by inhibition of thromboxane A2 synthesis.
    Skrinska VA; Konieczkowski M; Gerrity RG; Galang CF; Rebec MV
    Arteriosclerosis; 1988; 8(4):359-67. PubMed ID: 3134880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SQ 22536, an adenylate-cyclase inhibitor, prevents the antiplatelet effect of dazoxiben, a thromboxane-synthetase inhibitor.
    Bertelé V; Falanga A; Tomasiak M; Cerletti C; de Gaetano G
    Thromb Haemost; 1984 Feb; 51(1):125-8. PubMed ID: 6326343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The platelet-independent release of thromboxane A2 by Paf-acether from guinea-pig lungs involves mechanisms distinct from those for leukotriene.
    Lefort J; Rotilio D; Vargaftig BB
    Br J Pharmacol; 1984 Jul; 82(3):565-75. PubMed ID: 6430375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological studies on OKY-1581: a selective thromboxane synthetase inhibitor.
    Hiraku S; Wakitani K; Katsube N; Kawasaki A; Tsuboshima M; Naito J; Ujiie A; Komatsu H; Iizuka K
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():241-4. PubMed ID: 6221530
    [No Abstract]   [Full Text] [Related]  

  • 30. The pH dependent platelet utilization of arachidonic acid and a thromboxane A2 mimetic, in vitro.
    Kerry PJ; Paton CJ
    Pharmacol Res Commun; 1985 Jul; 17(7):609-18. PubMed ID: 3931104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biology and biochemistry of thromboxane synthetase inhibitors.
    Gorman RR
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():235-40. PubMed ID: 6221529
    [No Abstract]   [Full Text] [Related]  

  • 32. Different effects of thromboxane synthetase inhibitors on platelets from different individuals.
    Lancet; 1982 Nov; 2(8308):1156-7. PubMed ID: 6128469
    [No Abstract]   [Full Text] [Related]  

  • 33. Bleeding disorder associated with albumin-dependent partial deficiency in platelet thromboxane production. Effect of albumin on arachidonate metabolism in platelets.
    Rao AK; Koike K; Day HJ; Smith JB; Holmsen H
    Am J Clin Pathol; 1985 Jun; 83(6):687-96. PubMed ID: 3923822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
    Vezza R; Mezzasoma AM; Venditti G; Gresele P
    Thromb Haemost; 2002 Jan; 87(1):114-21. PubMed ID: 11848439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Irreversible inhibition of thromboxane (TX) A2 synthesis by Y-20811, a selective TX synthetase inhibitor.
    Mikashima H; Ochi H; Muramoto Y; Hirotsu K; Arima N
    Biochem Pharmacol; 1992 Jan; 43(2):295-9. PubMed ID: 1739418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet reactivity in vitro in relation to thromboxane in healthy pregnancy.
    Horn EH; Hardy E; Cooper J; Heptinstall S; Rubin PC
    Thromb Haemost; 1996 Feb; 75(2):346-51. PubMed ID: 8815588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dazoxiben examined for platelet inhibitory effect in an artificial circulation.
    Goldman M; Hall C; Hawker RJ; McCollum CN
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):61S-65S. PubMed ID: 6681706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of arachidonate metabolism by selected compounds in vitro with particular emphasis on the thromboxane A2 synthase pathway.
    Tobias LD; Hamilton JG
    Adv Prostaglandin Thromboxane Res; 1980; 6():453-6. PubMed ID: 6770605
    [No Abstract]   [Full Text] [Related]  

  • 39. UK-37, 248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity.
    Randall MJ; Parry MJ; Hawkeswood E; Cross PE; Dickinson RP
    Thromb Res; 1981 Jul 1-15; 23(1-2):145-62. PubMed ID: 6795753
    [No Abstract]   [Full Text] [Related]  

  • 40. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
    De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.